IP Verse

Method Of Assessing Risk Of Pml - EP2715352

The patent EP2715352 was granted to Biogen Idec MA on Apr 24, 2019. The application was originally filed on May 31, 2012 under application number EP12792375A. The patent is currently recorded with a legal status of "Revoked".

EP2715352

BIOGEN IDEC MA
Application Number
EP12792375A
Filing Date
May 31, 2012
Status
Revoked
Feb 17, 2023
Publication Date
Apr 24, 2019
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status

Get instant alerts for new oppositions and patent status changes

POLPHARMA BIOLOGICSJan 17, 2020WICHMANNADMISSIBLE

Patent Citations (5) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication Number
INTERNATIONAL-SEARCH-REPORTUS6238859
INTERNATIONAL-SEARCH-REPORTWO2011085369
OPPOSITIONWO2011085369
OPPOSITIONWO2012166971
SEARCHWO2011085369

Non-Patent Literature (NPL) Citations (14) New

NPL citations refer to non-patent references such as research papers, articles, or other publications cited during examination or opposition phases.

Citation PhaseReference Text
EXAMINATION- DOBBS TRUDY ET AL, "Performance characteristics of the immunoglobulin G-capture BED-enzyme immunoassay, an assay to detect recent human immunodeficiency virus type 1 seroconversion.", JOURNAL OF CLINICAL MICROBIOLOGY JUN 2004, (200406), vol. 42, no. 6, ISSN 0095-1137, pages 2623 - 2628
OPPOSITION- TAN CS et al., "Beyond progressive multifocal leukoencephalopathy: expanded pathogenesis of JC virus infection in the central nervous system", Lancet Neurol., (20100000), vol. 9, no. 4, pages 425 - 437, XP055673030
OPPOSITION- WRIGHT P.F., "STANDARDISATION AND VALIDATION OF ENZYME-LINKED IMMUNOSORBENT ASSAY TECHNIQUES FOR THE DETECTION OF ANTIBODY IN INFECTIOUS DISEASE DIAGNOSIS", Rev. sci. tech. Off. int. Epiz., (19930000), vol. 12, no. 2, pages 435 - 450, XP008036954
OPPOSITION- WARNKE C et al., "Natalizumab and progressive multifocal leukoencephalopathy: what are the causal factors and can it be avoided?", Arch. Neurology, (20100000), vol. 67, no. 8, pages 923 - 930, XP009146630
OPPOSITION- GORELIK L. et al., "Anti-JC virus antibodies: Implications for PML Risk Stratification", Ann Neurology, (20100000), vol. 68, no. 3, pages 295 - 303, XP055136721
OPPOSITION- PLAVINA T. et al., "Multi-site analytical validation of an assay to detect anti-JCV antibodies in human serum and plasma", J Clinical Virology, (20120100), vol. 53, page 71, XP028391942
OPPOSITION- DOBBS T. et al., "Performance Characteristics of the Immunoglobulin G-Capture BED-Enzyme Immunoassay, an Assay To Detect Recent Human Immunodeficiency Virus Type 1 Seroconversion", J Clinical Microbiology, (20040600), vol. 42, no. 6, pages 2623 - 2628, XP055673024
OPPOSITION- BROWN BA et al., "Natalizumab in the treatment of multiple sclerosis", Therapeutics and Clinical Risk Manaqement, (20090000), vol. 5, pages 585 - 594, XP055673034
OPPOSITION- FOX R., "Advances in the management of PML: focus on natalizumab", Cleveland Clinic Journal of Medicine, (20111100), vol. 78, no. 2, pages S33 - S37, XP055189309
SEARCH- Plavina T ET AL, "Anti-JCV antibody index further defines PML risk in natalizumab-treated MS patients The 27th Annual Meeting of the Consortium of Multiple Sclerosis Centers ACKNOWLEDGMENTS", Accessed March Neurology. Neurology. Warnke C J Neurol Neurosurg Psychiatry Ann Neurol, (20130530), pages 1736 - 1742742, URL: https://cmscactrims.confex.com/cmscactrims/2013/webprogram/Handout/Paper1642/Plavina_Tysabri JCV Ab Index_2013 CMSC Poster_FINAL.pdf, (20150519), XP055190187 [T] 1,2,9-21 * column 4, paragraph 1 *
SEARCH- SANDROCK ALFRED ET AL, "Risk Stratification for Progressive Multifocal Leukoencephalopathy (PML) in MS Patients: Role of Prior Immunosuppressant Use, Natalizumab-Treatment Duration, and Anti-JCV Antibody Status", NEUROLOGY, & 63RD ANNUAL MEETING OF THE AMERICAN-ACADEMY-OF-NEUROLOGY; HONOLULU, HI, USA; APRIL 09 -16, 2011, (201103), vol. 76, no. 9, Suppl. 4, ISSN 0028-3878, page A248, XP055189963 [X] 1,2 * Fig 3 ; col 4, para "Conclusions" * [I] 9-21
SEARCH- SUBRAMANYAM MEENA ET AL, "Anti-JCV Antibodies Are Consistently Detected Prior to and after PML Diagnosis in Natalizumab-Treated MS Patients", NEUROLOGY, & 63RD ANNUAL MEETING OF THE AMERICAN-ACADEMY-OF-NEUROLOGY; HONOLULU, HI, USA; APRIL 09 -16, 2011, (201103), vol. 76, no. 9, Suppl. 4, ISSN 0028-3878, pages A636 - A637, XP008176353 [X] 1,2 * abstract * [I] 9-21
SEARCH- WARNKE CLEMENS ET AL, "Natalizumab and progressive multifocal leukoencephalopathy: what are the causal factors and can it be avoided?", ARCHIVES OF NEUROLOGY,, (20100801), vol. 67, no. 8, doi:10.1001/ARCHNEUROL.2010.161, pages 923 - 930, XP009146630 [X] 1,2 * page 926, column 2, paragraph l - page 927, column 2, paragraph 1 * [I] 9-21
SEARCH- LEONID GORELIK ET AL, "Anti-JC virus antibodies: Implications for PML Risk Stratification", ANNALS OF NEUROLOGY, (20100824), vol. 68, no. 3, doi:10.1002/ana.22128, ISSN 0364-5134, pages 295 - 303, XP055136721 [X] 1,2,9-11,13,15,18-20 * abstract ; pg 296, col 1, last para ; pg 300, col 1, para 1 & para bridging col 2 ; pg 301, col 2, lines 1-3 ; Table 1 ; Fig 6 * [I] 12,14,16,17,21

Download Citation Report

Get a free citation report including examiner, opposition, and international search citations.

Get Citation Report

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents